Mebeverinehydrochloride Aurobindo

Mebeverine Hydrochloride, the active ingredient in Mebeverinehydrochloride Aurobindo, is an antispasmodic presented as an unspecified strength tablet for oral use. It relieves abdominal pain and irregular bowel habits associated with irritable bowel syndrome and other functional bowel disorders in adult patients.

GNH USA supplies Mebeverinehydrochloride Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards.

Mebeverine Hydrochloride acts on the gastrointestinal smooth muscle to reduce spasm in functional bowel conditions. - Irritable bowel syndrome: lessens abdominal cramping and improves stool consistency. - Functional bowel disorders: alleviates spasms and discomfort without affecting normal motility. - Spastic colon: relaxes gastrointestinal smooth muscle to diminish pain and urgency.

Mebeverine Hydrochloride may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dry mouth: reduced salivation. - Headache: occasional tension‑type pain. - Dizziness: brief light‑headed sensations. - Abdominal pain: mild discomfort. - Constipation: reduced bowel frequency.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, or angioedema. - Severe hypotension: marked drop in blood pressure. - Cardiac arrhythmia: rare irregular heartbeats. - Hepatic injury: uncommon liver enzyme elevation.

Before prescribing Mebeverine Hydrochloride, clinicians should consider several safety aspects. - Hypersensitivity: avoid in patients with known allergy to mebeverine or excipients. - Hepatic impairment: use with caution; monitor liver function. - Renal impairment: adjust if severe renal dysfunction is present. - Concomitant anticholinergics: monitor for additive antispasmodic effects. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Mebeverine Hydrochloride has a limited interaction profile, but some combinations require attention.

Major Interactions (Avoid): - None well documented: no strong contraindicated drug combinations have been identified.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may enhance antispasmodic effect and increase dry‑mouth risk. - Other antispasmodics: additive smooth‑muscle relaxation could lead to excessive GI hypomotility. - CYP3A4 inhibitors (e.g., ketoconazole): may raise mebeverine plasma levels. - CYP3A4 inducers (e.g., rifampicin): may reduce therapeutic effectiveness.